AMPLY Discovery leverages evolution and machine learning to discover new drugs through technology that digitizes biological diversity using next-generation sequencing.

AMPLY Discovery

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Exscientia plc

Iktos leverages AI and robotics to transform drug discovery, integrating Generative AI with automated synthesis and testing to accelerate development of new treatments.

Iktos

Sherlock Biosciences engineers biology to deliver products for molecular diagnostics, aiming to democratize and decentralize testing to personalize healthcare and impact global health.

Sherlock Biosciences

Novel Biologics. Designed by Evolution. Discovered by AI.

AMPLY Discovery uses machine learning and synthetic biology to mine vast biological data to discover novel biologic drug and nutraceutical candidates. Using a proprietary in silico and in vitro hybrid platform to discover best-in-class molecules AMPLY is helping tackle some of humankind's greatest challenges such as cancer, MDR infections and metabolic diseases.

Based in Belfast, Northern Ireland. Spin out from Queen's University Belfast.

Innovate UK

Co-FundNI

QUBIS Innovation Fund

Halo Business Angel Network

Helix Way

Explain the AMPLY Discovery platform to a non-scientist!

Dr Ben Thomas describes how the AMPLY Discovery technology uses AI to speed up the process of finding new effective ways to kill disease threats.

Bacterial infections could kill 10 million a year by 2050, so we need faster ways to develop new drugs. AMPLY Discovery is at the forefront of groundbreaking new technologies, combining AI, genomics and synthetic biology.

Read our carousel to understand more!

#amplydiscovery #ai #drugdiscovery #startup


AMPLY Discovery will be one of the leading NI-based start ups pitching at the Deep tech Summit in Belfast on 16th November. 

We look forward to catching up with friends and talking about our drug discovery programmes with investors. 

If you want to catch up, or fancy a nice night out in Belfast you can register to attend. Anne Dornan Dr. Cecilia Hegarty Paul Donachy QUBIS Ltd Brian McCaul https://lnkd.in/eUGESxVT 

We are thrilled to share that AMPLY Discovery has been selected as one of 12 “exceptional AI startups”, to participate in the Techstars Chicago, powered by J.P. Morgan program. 

This accelerator is for early-stage companies that use Artificial Intelligence to address global problems, scale businesses, and design new business models.

We will have the chance to work alongside some of the brightest minds, receive world-class mentorship, and access invaluable resources to accelerate the growth of Amply Discovery.

Here’s a comment from Tricia Martínez-Saab, Managing Director of Techstars. 

“Artificial Intelligence is revolutionary technology that can be used as a tool to fight some of our greatest challenges. Now more than ever we need novel innovative out of the box solutions that can move the needle. Our 12 portfolio companies for Techstars Chicago powered by J.P. Morgan are pushing the boundaries on what is possible with Artificial Intelligence.” 

We look forward to sharing our progress, insights, and learnings along the way.

Please feel free to reach out if you'd like to connect or collaborate!

#AI #syntheticbiology #StartUp #AcceleratorProgram


Metric
Company Name	AMPLY Discovery	Exscientia plc	Iktos	Sherlock Biosciences
Symbol		EXAI
MSH ID	COM:AMPLYDISCOVERY	AI:EXSCIENTIA	AI:IKTOS	BIO:SHERLOCK
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Pharmaceuticals	Biotechnology
Country	GB	GB	FR	US
Stage
Employee Count	7	483		75
Website	amplydiscovery.com	exscientia.ai	iktos.ai	sherlock.bio
LinkedIn				sherlock-biosciences
Founders

Metric
Market Cap		723.67M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		24.96M
Revenue (LTM)
Revenue (NTM)
Gross Profit		-28.48M
EBITDA		-204.14M
Operating Income		-223.52M
Net Income		-181.44M
EPS		-1.46
Diluted EPS		-1.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		-0.28
Operating Profit Margin		-7.14
EBITDA Margin		-8.18
Net Profit Margin		-5.88
Return on Equity		-0.33
Return on Assets		-0.27
Return on Capital Employed		-0.38

COM:AMPLYDISCOVERY

AMPLY Discovery

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-3.75
P/B Ratio		1.45
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		30.42
EV Multiple		-4.45

Metric
Days Sales Outstanding		992.91
Days Payables Outstanding		114.19
Days Inventory Outstanding		0.00
Operating Cycle		992.91
Cash Conversion Cycle		878.72
Asset Turnover		0.05

Metric
Operating Cash Flow		-146.19M
Free Cash Flow		-179.32M
Cash Flow to Debt		-4.68
Operating Cash Flow/Sales		-4.76
Free Cash Flow Yield		-0.37

Metric
Cash & Equivalents		330.76M
Accounts Receivable		-8.67M
Inventory		1
Goodwill		7.89M
Debt to Capitalization		0.07
Debt to Assets		0.03
Current Ratio		6.67
Quick Ratio		6.58

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		1.18
R&D to Revenue		5.40
SG&A to Revenue		1.69